SYMJEPI — Class I drug recall D-0763-2022
Terminated recall by Adamis Pharmaceuticals Corporation, reported 2022-04-13, distributed nationwide. Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.
| Recall number | D-0763-2022 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Adamis Pharmaceuticals Corporation, San Diego, CA, United States |
| Recall initiated | 2022-03-21 |
| Classified | 2022-04-08 |
| Reported by FDA | 2022-04-13 |
| Terminated | 2023-02-08 |
| Distributed | Nationwide (US) |
| Quantity | 25,103 cartons |
| NDC | 78670-0130-02 |
| Lot numbers | 21041W, 21081W, 21102W |
| Expiration dates | 2022-08-31, 2022-11-30, 2023-02-28 |
Product
SYMJEPI (epinephrine injection, USP) 0.3 mg, (0.3 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Louisville, KY 40241, Made in Belgium, NDC 78670-130-02
Reason for recall
Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0763-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.